喹啉,4-(1-氯乙基)- | 117125-17-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 喹啉,4-(1-氯乙基)-
• 英文名称: 4-(1-chloro-ethyl)-quinoline
• 英文别名: 4-(1-Chlor-aethyl)-chinolin；4-(1-Chloroethyl)quinoline
• CAS: 117125-17-4
• 化学式: C₁₁H₁₀ClN
• 分子量: 191.66
• InChiKey: MCMXEYRHRXGSGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  喹啉,4-(1-氯乙基)- 以16%的产率得到
  参考文献：
  名称：

  RODRIGUEZ, J. G.;BENITO, Y., J. HETEROCYCL. CHEM., 25,(1988) N 3, C. 819-821

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氯化亚砜 、 乙醚 作用下， 生成 喹啉,4-(1-氯乙基)-
  参考文献：
  名称：

  Syntheses in the Quinoline Series. III. The Nitration of 2-Chloro-4-methylquinoline and the Preparation of Some 2-Hydroxy-4-methyl-8-(dialkylaminoalkyl)-aminoquinolines

  摘要：

  DOI：

  10.1021/ja01856a003

文献信息

• Imidazole and imidazoline derivatives and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05866579A1

  公开（公告）日：1999-02-02

  This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human .alpha..sub.2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the .alpha..sub.2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  本发明涉及新型咪唑和咪唑啉衍生物，它们是选择性激动剂，用于克隆的人类α2肾上腺素受体。本发明还涉及使用这些化合物治疗任何需要调节α2受体的疾病。该发明还提供了一种药物组合物，包括上述定义的化合物的治疗有效量和药用载体。
• Imidazoline derivatives and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06294566B1

  公开（公告）日：2001-09-25

  This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  这项发明涉及新型咪唑和咪唑啉衍生物，它们是选择性激动剂，可作用于克隆的人类α2肾上腺素受体。此发明还涉及使用这些化合物治疗任何需要调节α2受体的疾病。此发明还提供了一种药物组合物，包括上述定义化合物的治疗有效量和药学可接受的载体。
• Novel cyclic compound having quinolylalkylthio group
  申请人：Kawashima Kenji

  公开号：US20080021064A1

  公开（公告）日：2008-01-24

  The present invention relates to a synthesis study of novel cyclic compounds having a quinolylalkylthio group represented by the formula (1), and pharmacological actions of the compounds. In the formula, the ring X represents: which may have halogen and/or alkyl; R 1 and R 2 independently represent hydrogen, alkyl, cycloalkyl, aryl or a (non) aromatic heterocycle; R 3 represents qinolyl; A represents sulfur, sulfinyl or sulfonyl; and B represents alkylene.

  本发明涉及一种合成具有式（1）所表示的喹诺基烷基硫基的新型环状化合物的研究，以及所述化合物的药理作用。在该式中，环X代表：可能具有卤素和/或烷基；R1和R2独立地表示氢、烷基、环烷基、芳基或（非）芳香杂环；R3表示喹诺基；A表示硫、亚砜或磺酰基；B表示烷基。
• Nickel‐Catalyzed Stereo‐ and Enantioselective Cross‐Coupling of <i>gem</i> ‐Difluoroalkenes with Carbon Electrophiles by C−F Bond Activation
  作者：Ziqi Zhu、Lin Lin、Jieshuai Xiao、Zhuangzhi Shi

  DOI：10.1002/anie.202113209

  日期：2022.2

  AbstractStereo‐ and enantioselective cross‐electrophile coupling involving C−F bond activation is reported. Treatment of gem‐difluoroalkenes with racemic benzyl electrophiles in the presence of a chiral nickel complex using B2pin2 as a stoichiometric reductant allows the construction of a C(sp2)−C(sp3) bond under mild conditions, affording a broad range of monofluoroalkenes bearing stereogenic allylic centers. Initial mechanistic studies indicate that a radical chain pathway may be operating, wherein the ester group in the gem‐difluoroalkene promotes C−F bond activation through oxidative addition to a Ni species.
• Rodriguez, J. G.; Benito, Y., Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 819 - 821
  作者：Rodriguez, J. G.、Benito, Y.

  DOI：——

  日期：——